Haematologica (Jan 2024)

Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors

  • Yuqin Song,
  • Junning Cao,
  • Qingyuan Zhang,
  • Caixia Li,
  • Lugui Qiu,
  • Junyuan Qi,
  • Huilai Zhang,
  • Wenyu Li,
  • Lihong Liu,
  • Hongmei Jing,
  • Keshu Zhou,
  • Weijing Zhang,
  • Liling Zhang,
  • Daqi Li,
  • Liqun Zou,
  • Haiyan Yang,
  • Wenbin Qian,
  • Hui Zhou,
  • Jianda Hu,
  • Hongyan Yin,
  • Sisi Fu,
  • Songhua Fan,
  • Qian Xu,
  • Jian Wang,
  • Xiaoyun Jia,
  • Guangxiu Dai,
  • Weiguo Su,
  • Jun Zhu

DOI
https://doi.org/10.3324/haematol.2022.282401
Journal volume & issue
Vol. 999, no. 1

Abstract

Read online

Sovleplenib (HMPL-523) is a selective spleen tyrosine kinase (Syk) inhibitor with antitumor activity in preclinical models of B-cell malignancy. We conducted a dose-escalation and dose-expansion phase I study of sovleplenib in patients with relapsed/refractory mature Bcell tumors. Dose escalation followed a 3+3 design; patients received oral sovleplenib (200-800 mg once daily [q.d.] or 200 mg twice daily [b.i.d.], 28-day cycles). During dose expansion, patients were enrolled into four cohorts per lymphoma classification and treated at the recommended phase 2 dose (RP2D). Overall, 134 Chinese patients were enrolled (dose escalation, n=27; dose expansion, n=107). Five patients experienced dose-limiting toxicities: one each of amylase increased (200 mg q.d.), febrile neutropenia (800 mg q.d), renal failure (800 mg q.d.), hyperuricemia and blood creatine phosphokinase increased (200 mg b.i.d.) and blood bilirubin increased and pneumonia (200 mg b.i.d.). RP2D was determined as 600 mg (>65 kg) or 400 mg (≤65 kg) q.d. The primary efficacy end point of independent review committee–assessed objective response rate in indolent B-cell lymphoma was 50.8% (95% CI, 37.5–64.1) in 59 evaluable patients at RP2D (follicular lymphoma: 60.5%, marginal zone lymphoma: 28.6%, lymphoplasmacytic lymphoma/Waldenström macroglobulinemia, 0%). The most common (≥10% patients) grade ≥3 treatment-related adverse events in the doseexpansion phase were decreased neutrophil count (29.9%), pneumonia (12.1%) and decreased white blood cell count (11.2%). Pharmacokinetic exposures increased doseproportionally with ascending dose levels from 200–800 mg, without observed saturation. Sovleplenib showed antitumor activity in relapsed/refractory B-cell lymphoma with acceptable safety. Further studies are warranted.